SCHEMBL2649449

SCHEMBL2649449

CCOC(=O)c1c(C(C)C)nc(C(C)C)c(C(=O)OCC)c1-c1ccccc1C#C[Si](C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
ALDH1A1 P00352 4/20 0.42
LMNA P02545 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
APAF1 O14727 1/20 0.42
MITF O75030 1/20 0.42
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
KDM4E B2RXH2 2/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
SLC10A2 Q12908 1/20 0.39
TDP2 O95551 1/20 0.39
NSD2 O96028 1/20 0.39
THRB P10828 1/20 0.39
XBP1 P17861 1/20 0.39
HTT P42858 1/20 0.39
GALK1 P51570 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2648375 0.85 MAPT (0.43) MAPTALDH1A1LMNASMN1; SMN2APAF1
SCHEMBL2649452 0.80 HTT (0.46) MAPTALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL2647828 0.79 MAPT (0.46) MAPTALDH1A1LMNASMN1; SMN2APAF1
SCHEMBL8949567 0.76 MAPT (0.69) MAPTALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL2648334 0.73 PTGER1 (0.45) MAPTALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL2649163 0.73 MAPT (0.36) MAPTALDH1A1LMNASMN1; SMN2APAF1
SCHEMBL2649161 0.73 MAPT (0.36) MAPTALDH1A1LMNASMN1; SMN2APAF1
SCHEMBL25308678 0.71 ALDH1A1 (0.47) MAPTALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL2662913 0.71 GCGR (0.65)
SCHEMBL31234653 0.71 ALDH1A1 (0.47) MAPTALDH1A1LMNASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed